dilation, 2 minutes, 2 hours and 24 hours after delivery. Cord blood cortisol and pH were also obtained. Modes of delivery, complications during labor and delivery, and early neonatal outcomes were also evaluated. RESULTS: Salivary cortisol levels increased gradually from latent phase to active phase (Fig. 1) . The maximum increase was observed within two minutes of the delivery (from an average of 1.06 mcg/dl to 1.67 mcg/dl: 57% increase). Within two hours from the delivery, cortisol decreased and reached a non-gravid level after 24 hours (0.16 mcg/dl). Cortisol levels during labor and up to 2 hours postpartum were above the average level of non-gravid women (0.5 mcg/dl). Nulliparous had significantly higher cortisol levels compared to multiparas when measured 2 minutes (p¼0.03) and 2 hours postpartum (p¼0.041), with no difference 24 hours after the delivery (p¼0.666) (Fig. 2) . Women with epidural had lower cortisol levels at a complete dilation (p¼0.026) and 2 hours postpartum (p¼0.016) compared to women without epidural. Cortisol levels 24 hours postpartum were similar in patients delivered with or without epidural analgesia (p¼0.917). No difference was found in cortisol levels between women who had normal vaginal delivery (NVD) compared to cesarean delivery (CD), except for higher cortisol levels 2 hours after CD (mean 2 vs. 0.85, p¼0.035). Emotional stress peaks during latent and full dilation phases (mean 4.56, 4.29, respectively). Maximum decrease from 4.29 to 2.04 (52%) occurs immediately postpartum. There is a positive correlation between cord cortisol after vacuum extraction (p¼0.04) and no correlation between CD and NVD (p¼0.231). CONCLUSION: This study establishes a cortisol labor curve for low-risk pregnancies. Salivary cortisol may be used for further planning of ways to decrease stress during labor.
352 Association between regional analgesia and postpartum opioid use following vaginal delivery Nevert Badreldin, William A. Grobman, Lynn M. Yee
Northwestern University Feinberg School of Medicine, Chicago, IL OBJECTIVE: Regional analgesia is widely used and a highly effective modality for intrapartum pain management. However, the association of intrapartum regional analgesia with subsequent opioid use has not been described. We sought to evaluate whether use of intrapartum regional analgesia is associated with postpartum opioid utilization after vaginal delivery. STUDY DESIGN: Retrospective cohort study of all women who underwent vaginal delivery at a tertiary care center (12/2015-16) . Women were excluded if they had an allergy to NSAIDs or morphine. Inpatient records were queried for delivery details, patient demographic and clinical characteristics, and provider characteristics. Medication administration records were queried for time-tofirst opioid dose following delivery and opioid use during the postpartum hospitalization. Postpartum opioid use was converted to morphine milligram equivalents (MME) and analyzed as MME per day to standardize dosing over variable lengths of stay. Bivariable and multivariable Cox and linear regression models were used to examine the associations of regional analgesia with 1) time-to-first postpartum opioid dose and 2) daily inpatient postpartum opioid use. RESULTS: Of 9,038 eligible women who underwent vaginal delivery, 86.8% used intrapartum regional analgesia. Women who used regional analgesia had a longer mean time-to-first postpartum opioid dose (9.45 vs. 3.78 hours, p<0.001) ( Figure) . Of women who used an opioid in the postpartum period, the median MME per day for those who used regional analgesia was 15.83 ), compared to 13.78 MME per day for those who did not use regional analgesia (p¼0.113) (Table) . On multivariable Cox regression adjusting for potential confounders, use of regional analgesia was associated with a nearly 40% longer time-to-first opioid dose (aHR 0.63, 95% CI 0.55-0.72). Regional analgesia was not significantly associated with amount of daily opioid use (b -0.50, 95% CI -2.89 to 1.89). CONCLUSION: Following vaginal delivery, use of intrapartum regional analgesia is associated with a significant prolongation in time-to-first opioid dose but is not associated with a change in daily opioid use.
Poster Session II OBJECTIVE: Opioid use is common for the management of postpartum pain. We sought to evaluate patient factors associated with time to first opioid dose following delivery. STUDY DESIGN: Retrospective case control study of all women who underwent delivery at a large tertiary care center (12/2015-16). Women were excluded if they had a nonsteroidal anti-inflammatory drug (NSAID) or morphine allergy. Inpatient records were queried for mode of delivery, patient characteristics, time-to-first opioid dose, and time-to-first NSAID dose after delivery. Time-to-first opioid was compared by patient characteristics with bivariable Cox regressions; these characteristics included age, BMI, self-described race/ethnicity, insurance, nulliparity, marital status, and history of anxiety, depression, smoking, and substance use. Factors which were significantly associated with time-to-use (p 0.05) on bivariable analysis were included in multivariable Cox regression models to identify factors independently associated with time-to-first opioid dose. Women who underwent vaginal delivery (VD) and cesarean delivery (CD) were analyzed separately. RESULTS: A total of 7,962 women who underwent VD and 2,831 women who underwent CD were included. In the final regression model for women who underwent VD, greater time-to-first NSAID dose (aHR 1.34, 95% CI 1.18-1.51), greater BMI (aHR 1.02, 95% CI 1.02-1.03), nulliparity (aHR 1.10, 95% CI 1.02-1.19), and a history of smoking (aHR 1.24, 95% CI 1.10-1.40) were significantly associated with earlier time-to-first opioid dose (Table) . In the final regression model for women undergoing CD, only history of smoking (aHR 1.19, 95% CI 1.05-1.35) and depression (aHR 1.15, 95% CI 1.02-1.30) were significantly associated with earlier time-tofirst opioid dose (Figure) . Conversely, nulliparity (aHR 0.85, 95% CI 0.79-0.92) and Asian race (aHR 0.84, 95% CI 0.72-0.98) were associated with a significantly greater time-to-first opioid dose for women who had CD. CONCLUSION: The time-to-first opioid dose following delivery is associated with patient characteristics. Notably, in women who underwent VD, a later first NSAID dose was significantly associated with a decreased time-to-first opioid dose. This finding suggests the potential importance of considering multimodal pain management strategies in postpartum women as a means of delaying opioid exposure.
354 Neonatal outcomes after antenatal late preterm steroids in women with diabetes Nevert Badreldin, Andrea A. Henricks, Alan M. Peaceman, Lynn M. Yee
Northwestern University Feinberg School of Medicine, Chicago, IL OBJECTIVE: Women with diabetes mellitus (DM) were excluded from the sentinel trial demonstrating neonatal benefits of antenatal steroid administration in the late preterm period, yet many providers administer steroids to women with DM. Our objective was to evaluate neonatal outcomes associated with administration of antenatal late preterm steroids in women with DM. STUDY DESIGN: This is a retrospective cohort study of all women with singleton pregnancies who were admitted to the hospital between 34 0/7-36 6/7 weeks' gestation in periods before ("preprotocol": 11/ 2012-11/2013 ) and after ("postprotocol": 4/2016-4/2017) introduction of an institutional antenatal late preterm steroids protocol. Women were included if they had a diagnosis of pregestational or gestational DM. The primary outcome was neonatal hypoglycemia (glucose 60 mg/dL in the first 24 hours of life). Secondary outcomes included hypoglycemia 40 mg/dL, dextrose administration,
